for decades, a prominent “black box” warning on hormone therapy products has shaped perceptions and treatment decisions for menopausal women in the United States. Now, following a extensive review of accumulated data, the Food and Drug Administration is removing some of the strictest language from those labels, a move expected to spark renewed conversation between patients and their doctors. The shift acknowledges evolving scientific understanding of hormone therapy’s risks and benefits, though a warning regarding endometrial cancer will remain. This change, first reported November 10th, could offer new options for the 61 million women in the U.S. currently experiencing menopause or perimenopause, according to recent estimates from the North American Menopause Society.
For years, women in the United States opening a new box of hormone therapy for menopause were met with a stark black box warning about potential serious risks. Many women hesitated to begin treatment after reading it. Hot flashes, sleepless nights, brain fog, and mood swings became a daily reality for many, as medical opinion on hormone therapy shifted back and forth. Now, a change announced from Washington is prompting a reevaluation of those concerns.
The U.S. Department of Health and Human Services (HHS) announced that the Food and Drug Administration (FDA) will begin removing the strictest warnings from hormone therapies used in menopause. This decision follows a comprehensive review of clinical studies, expert panels, and a public comment period that reexamined two decades of data on the risks and benefits of these treatments. This shift in guidance could offer relief to millions of women experiencing menopausal symptoms.
The change means general references to increased risk of cardiovascular disease, breast cancer, and dementia for women taking these therapies will be removed from labeling. However, the warning about endometrial cancer will remain for products containing estrogen alone. This isn’t a green light for widespread hormone use, but rather an adjustment to the messaging based on current scientific understanding. As of now, according to reports, the National Administration of Medicines, Food and Medical Technology (Anmat) in Argentina has not yet commented on these developments.
The change doesn’t come as a surprise to the Buenos Aires Society of Obstetrics and Gynecology (Sogiba). The organization points out that the landmark Women’s Health Initiative (WHI) study, published in 2002, which initially prompted the warning, was conducted on a population of women over 63 years old and used a hormone combination no longer standard in menopause replacement therapy. They also state that the warning was broadly applied to all formulations and age groups, something that current evidence no longer supports. As the society stated, “They were extending a warning or recommendation to the use of all hormones as if they were all the same, and that is not the case.”
Alejandra Belardo, head of Climacteriology at the Gynecology Service of the Italian Hospital, explains that it’s important to understand what hormone therapy entails. “Hormone replacement therapy (HRT) is the substitution of female hormones – estrogen, progesterone – in postmenopausal women. Also in peri- and postmenopause, when they have symptoms related to climacteric or menopause,” the expert describes. She explains that today, estrogens are used via oral and transdermal routes, local preparations at the vaginal level, and progesterone in women with a uterus; in selected situations, androgens may be added if there is a decrease in sexual desire.
Belardo reviews what happened after the WHI study. She recalls that, following that research, the FDA incorporated a “black box” warning about increased breast cancer, more cardiovascular events, and more dementia. Over time, she adds, reanalyses of the same study and other trials showed that this extrapolation was excessive. That’s why, for two decades, specialists in climacteriology have been trying to explain that hormones can be beneficial when properly indicated.
“I’ve been working with menopause for thirty years. And I sometimes regret that many women have been deprived of the benefits of hormone therapy because of this fear, the hormone phobia, the fear of getting cancer or the fear of getting thrombosis, etc.,” she summarizes.
The gynecologist also emphasizes that estrogen and progesterone act far beyond the reproductive organs. “Estrogens have receptors in our body; there are receptors for estrogens and progesterone beyond what is the genital apparatus and what has to do with reproduction,” Belardo details. She mentions effects on the brain, bones, muscle mass, lipid profile, and blood pressure, which helps explain why a sudden drop in hormones can impact mood, sleep, the risk of osteoporosis, and cardiovascular health.
The FDA’s regulatory shift is supported, among other points, by a concept that is now central: the timing of treatment initiation. Romina Pesce, a physician in the Gynecology Service of the Italian Hospital, summarizes it this way: “The concept of the ‘window of opportunity’ for treatment choice in menopause refers to a defined period in which hormone therapy would offer a greater benefit than risk to the woman’s health.” That interval, she explains, includes women within the first ten years since their last menstruation or under 60 years of age.
Pesce points out that the explanation is physiological. In the early years of menopause, the endothelium – the inner layer of blood vessels – retains good function and the burden of atherosclerotic plaque (fat deposits that harden the arteries) is low. In that stage, she describes, estrogen acts as a vasodilator, anti-inflammatory, and antiatherogenic agent.
Available literature, the specialist maintains, shows that initiating therapy during this period can relieve hot flashes and sleep disturbances, improve mood, reduce cardiovascular and thrombotic risks, protect bone, and decrease fractures, and may even be associated with lower mortality from all causes. Observational studies, she adds, also suggest a possible neuroprotective effect when treatment begins near menopause.
Outside that window, the picture changes. Pesce warns that if hormones are started after age 60 or more than ten years after the last menstruation, thrombotic events and strokes increase, and the benefits are lost. In the neurological realm, even, therapy may increase the risk of dementia. Thus, “within the window of opportunity, HRT shows a favorable safety profile in healthy women, while outside that window, the risks increase and the benefits decrease.”
In light of decades of alarming messages, Pesce insists that advice from a specialist, personalization, and patient follow-up are key. She recalls that hormone therapy has risks, but that in well-selected women, they are low in absolute terms. “Points to monitor are venous thrombosis, especially with oral estrogens in patients with other risk factors; cardiovascular events in older women or with previous disease; and an increased risk of breast cancer with prolonged use of combination therapy for several years.” She also emphasizes the importance of adjusting the route of administration and the choice of progestin to protect the endometrium.
Rosana Molina, a physician in the Gynecology and Mastology Service of the German Hospital and in charge of the climacteric clinic, emphasizes the same idea from daily practice. “Menopausal hormone therapy is a tailored suit for each woman,” she underlines.
She describes that no patient should start treatment without a detailed evaluation including medical history, history of thrombosis, heart attack, stroke, breast or endometrial cancer, liver disease, and studies such as mammography, ultrasound, Pap smear, lipid profile, and blood glucose.
Molina lists absolute contraindications: a personal history of hormone-sensitive breast cancer or other estrogen-dependent neoplasms, severe liver disease, heart or kidney failure, systemic lupus erythematosus, idiopathic venous thrombosis or pulmonary embolism, and recent cardiovascular events. In those patients, she says, non-hormonal alternatives for hot flashes and local treatments for genitourinary symptoms are sought. She also differentiates the situations in which therapy can be indicated, but by non-oral routes, to avoid the first hepatic pass in women with diabetes, hypertension, or hypertriglyceridemia.
Sogiba closely followed the FDA review. The organization insists that the regulator’s new position recognizes something that evidence has been showing for years: that hormone therapy, when properly indicated, has clear benefits. “Finally, it is accepted that hormone replacement therapy prescribed to the indicated woman has many benefits and is no longer to be categorized as a higher risk,” they synthesize from the institution.
They reiterate that the WHI recruited a population that does not reflect the average woman who consults today for climacteric symptoms and used a hormone combination different from current therapies.
Thus, as the world’s most influential regulator corrects its warning, specialists are regaining a therapeutic tool with clear criteria, good follow-up, and evidence in hand.
